Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl. J. Merl 343(13), 938–952 (2000).
   Google Scholar
• •Current overview of multiple sclerosis (MS) therapies.
   Google Scholar
• CHAMPS Study Group. Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group. Mutt. Scler. 8(5), 405–409 (2002).
   PubMedGoogle Scholar
• Rudick RA, Cohen JA, Weinstock- Guttman B, Kinkel RP Ranshohoff RM. Management of multiple sclerosis. N Engl. Merl 337(22), 1604–1611 (1997).
   Google Scholar
• Beck RVV, Cleary PA, Anderson MM et al A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl. J Merl 326 (9), 581–588 (1992).
   Google Scholar
• Beck RVV, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch. Ophthalmol 111(6), 773–775 (1993).
   Google Scholar
• Beck RVV, Cleary PA, Trobe JD et al The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N. Engl. Merl 329 (24), 1764–1769 (1993).
   Google Scholar
• Frohman E, Phillips T, Kokel K et al Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. The Neurologist 8(4), 227–236 (2002).
   PubMedGoogle Scholar
• Kieseier BC, Hartung H-P Current disease- modifying therapies in multiple sclerosis. Semin. Aim& 23(2), 133–145 (2003).
   Google Scholar
• The IFN-0 Multiple Sclerosis Study Group. Interferon-3-1b is effective in relapsing—remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43(4), 655–661 (1993).
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon-0-1a for disease progression in relapsing multiple sclerosis. Ann. Neural. 39(3), 285–294 (1996).
   Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon-p- la Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon-0-la in relapsing/remitting multiple sclerosis. Lancet 352(9139), 1498–1504 (1998).
   Google Scholar
• Johnson IQ, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing—remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7), 1268–1276 (1995).
   Google Scholar
• Johnson IQ, Brooks BR, Cohen JA et al. Extended use of glatiramer acetate (Copaxone) is well-tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. The Copolymer 1 Multiple Sclerosis Study Group. Neumlogy50(3), 701–708 (1998).
   Google Scholar
• Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. The Cochrane Libraryl, 1–25 (2004).
   Google Scholar
• Polman CH, Uitdehaag BM. New and emerging treatment options for multiple sclerosis. Lancet Neural. 2(9), 563–566 (2003).
   Google Scholar
• Miller DH, Khan OA, Sheremata WA et al A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl. I Merl 348(1), 15–23 (2003). Most detailed publication on a Phase 11 clinical trial with natalizumab.
   Google Scholar
• Tubridy N, Behan PO, Capildeo R et al. The effect of antia4 integrin antibody on brain lesion activity in MS. Neurology 53(3), 466–472 (1999).
   Google Scholar
• ••Phase 11 data on natalizumab in 72 patients with MS.
   Google Scholar
• Wolinsky JS. Rational therapy for relapsing multiple sclerosis. Lancet Neural 2(5), 271–272 (2003).
   PubMedGoogle Scholar
• Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52(5), 1072–1074 (1999).
   PubMed Web of Science ®Google Scholar
• ••Phase I data on natalizumab.
   Google Scholar
• Ghosh S, Goldin E, Gordon PH et al. Natalizumab for active Crohn's disease. N Engl. Med. 348(1), 24–32 (2003).
   Google Scholar
• Gordon PH, Hamilton MI, Donoghue S et al A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to a-4 integren. Aliment. Pharmacol Thec 16(4), 699–705 (2002).
   Google Scholar
• Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting a-4 integren. Am. J. Castroenteml 98(11), 2372–2382 (2003).
   Google Scholar
• Dalton CM, Miszkiel IKA, Barker et al Effect of natalizumab on conversion of gadolinium enhancing lesions to Ti hypointense lesions in relapsing multiple sclerosis. J. Neural (2004) (In Press).
   Google Scholar
• Polman C, Havrdova E, Hutchinson M et al. Baseline patient characteristics of the AFFIRM study: a study designed to determine the efficacy and safety of natalizumab (AntegrenTm) for the treatment of relapsing—remitting multiple sclerosis. Poster presented at the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 17-20 September, Milan, Italy (2003).
   Google Scholar
• McDonald WI, Compston A, Edan Get al Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neural 50(1), 121–127 (2001).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Calabresi P, Confavreux C et al Baseline characteristics of the SENTINEL study: a study designed to determine the efficacy and safety of natalizumab (AntegrenTm) in combination with interferon-0-1a (Avonex) for the treatment of relapsing—remitting multiple sclerosis (RRMS). Poster presented at the 19th Congress of the European Committee for Tmotrnent and Research in Multiple Sclerosis. 17–20, September, Milan, Italy (2003).
   Google Scholar
• Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA. An open-label trial of combination therapy with interferon-0-1a and oral methotrexate in MS. Neurology58(2), 314–317 (2002).
   Google Scholar
• Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A. Combination of cyclophosphamide and interferon-0 halts progression in patients with rapidly transitional multiple sclerosis. J. Neural Neumsurg. Psych. 71(3), 404–407 (2001).
   Google Scholar
• Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R. Azathioprine and interferon-0-1a in relapsing—remitting multiple sclerosis patients: Increasing efficacy of combined treatment. Ewa New& 51(1), 15–20 (2004).
   Google Scholar
• Fernández 0, Guerrero M, Mayorga C et al Combination therapy with interferon-0-lb and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. I Neural 249(8), 1058–1062 (2002).
   Google Scholar
• Leone DR, Giza K, Gill A et al. An assessment of the mechanistic differences between two integrin a401 inhibitors, the monoclonal antibody TA-2 and the small molecule BI05192, in rat experimental autoimmune encephalomyelitis. Pharmacol Exper. Ther. 305 (3), 1150–1162 (2003).
   Google Scholar